SANTA ROSA -- TriVascular announced today the first U.S. clinical study of its abdominal stent graft, a device that promises to significantly increase the pool of candidates for minimally invasive treatment of aortic aneurisms.
The first test using TriVascular's Ovation Abdominal Stent Graft was performed at the Prairie Heart Institute at St. John's Hospital in Springfield, Ill.
According to Dr. Mishkel, co-director of the Cardiac Catheterization Lab, the device performed very well and was easy to use.
"We are tremendously excited to begin U.S. clinical work," said TriVascular president and CEO Mike Chobotov. "We are encouraged by the enthusiasm of our clinical investigators and feel fortunate to be partnering with some of the top physicians in the country."
The Ovation is currently undergoing clinical testing in Europe, where it's expected to launch by the end of this year. The global market for abdominal stent systems is predicted to soon reach $2 billion.
To deal with anticipated demand 233-employee TriVascular will add 100 jobs in Santa Rosa during the next nine months, plus additional staff for a subsidiary already established in Switzerland.
